Safety and Dystrophin Expression of SPOT-mRNA03 in Duchenne Muscular Dystrophy (DMD) Patients — StellaEarly Phase 1 — Very small initial tests in humans, typically just a few people, to make sure the treatment is safe enough to study further.
Trial locations(1 site)
China
Shanghai Children's Medical Center, Shanghai, Shanghai Municipality Age range
2 Years – 6 Years
Last updated September 2025